



WORLD MEDICAL INNOVATION FORUMSM
CANCER | APRIL 25–27, 2016

PARTNERS HEALTHCARE

Headquartered in Boston, Massachusetts, Partners HealthCare is one of the nation's most highly regarded hospital systems. Its founding institutions, Brigham and Women's Hospital and Massachusetts General Hospital, are staffed by Harvard Medical School faculty and have a legacy of innovation that includes 18 Nobel Laureates and therapies that have redefined the contemporary standard of care. It's the largest academic research enterprise in the nation at more than \$1.5 billion of annual research. Its staff is responsible for hundreds of products and best practices that benefit millions of patients worldwide.

World Medical Innovation Forum

The World Medical Innovation Forum is a global gathering of more than 1,200 senior health care leaders hosted by Partners HealthCare in the heart of Boston. It was established to respond to the intensifying transformation of health care and its impact on innovation. The Forum is rooted in the belief that no matter the magnitude of that change, the center of health care needs to be a shared, fundamental commitment to collaborative innovation – industry and academia working together to improve patient lives.

The 2016 World Medical Innovation Forum will feature the newest technologies to diagnose, treat and manage cancer.

CANCER | April 25–27, 2016

CARDIOVASCULAR | May 1–3, 2017

Keynoters



Joseph Jimenez
CEO, Novartis

Robert Bradway
CEO, Amgen

Robert Mulroy
CEO, Merrimack Pharmaceuticals

Briggs Morrison, MD
CEO, Syndax Pharmaceuticals

David Lee
CEO, Lumicell

Marc de Garidel
Chairman and CEO, Ipsen

Paul Hudson
President, AstraZeneca US,
Executive Vice President,
AstraZeneca North America

David Torchiana, MD
CEO, Partners HealthCare

Daniel Haber MD, PhD
Director, Massachusetts General Hospital
Cancer Center, Kurt J. Isselbacher/Peter D.
Schwartz Professor of Oncology,
Harvard Medical School

Glenn Dranoff, MD
Global Head of Exploratory Immuno-
Oncology, Novartis Institutes for
Biomedical Research

Christopher Viehbacher
Managing Partner, Gurnet Point Capital

Henri Termeer

Jean-François Formela, MD
Partner, Atlas Venture

Bob Tepper, MD
Partner, Third Rock Ventures

Kathy Giusti
Founder and Executive Chairman, MMRF

Giovanni Caforio, MD
CEO, Bristol-Myers Squibb

Richard Gonzalez
CEO, AbbVie

Michael Pellini, MD
CEO, Foundation Medicine

David Schenkein, MD
CEO, Agios Pharmaceuticals

Bruno Strigini
President, Novartis Oncology

William Hait, MD, PhD
Global Head, Janssen R&D, J&J

Gary Reedy
CEO, American Cancer Society

Thomas Lynch, MD
CEO, Mass General
Physician's Organization

Monica Bertagnolli, MD
Chief, Division of Surgical Oncology,
Brigham and Women's Hospital,
Professor of Surgery,
Harvard Medical School

Judy Salerno, MD
CEO, Susan G. Komen for the Cure

William Sellers, MD
Vice President and Global Head of
Oncology, Novartis Institutes for
BioMedical Research

Nancy Snyderman, MD
Medical Advisor,
GE Healthymagination

Amir Nashat, PhD
Managing Partner, Polaris Partners

Jim Robinson
President, Americas Operations, Astellas

Francis Cuss, MD
Executive Vice President and
Chief Scientific Officer, R&D,
Bristol-Myers Squibb

Every Speaker an Expert. Every Panel Unique.
Every Seat Invaluable.

Featured speakers include more than 100 CEOs, top cancer innovators,
leading investors, and national journalists.

Sponsors

PRESENTING




STAKEHOLDER



STRATEGIC



COLLABORATORS



EXCLUSIVE MEDIA PARTNER



Panels

MON. APRIL 25, 2016

8:00 AM - 8:00 PM

TUES. APRIL 26, 2016

8:15 AM - 6:30 PM

WED. APRIL 27, 2016

8:10 AM - 12:35 PM

A War or Moonshot: Where Do We Stand?

Arms Race in Radiation

Breakthrough Devices to Treat Cancer

Cancer Diagnostics: New Uses, New Reimbursements?

Combination Cancer Therapies: Drug Resistance and Therapeutic Index

Creating a Disruptive Cancer Pipeline

Curative Therapies: The Economics of Game Changing Science

Discovery Café: Enjoy Lunch with Top Cancer Leadership from across Partners HealthCare

Disruptive Dozen

Early Detection and Prevention of Cancer

Epigenetics and Novel Cancer Targets

Financing Breakthrough Cancer Companies

First Look: The Next Wave of Cancer Breakthroughs

Global Cancer Markets

Immunotherapy I: Checkpoint Activation and Cancer Vaccines

Immunotherapy II: Cell Based Therapies

New Philanthropy: Patients Driving Innovation

Study Designs to Meet the Challenges of Personalized Cancer Medicine

Surviving Cancer: New Realities, New Needs

Winning Portfolio Strategy

Breakthrough Technologies

First Look

The Next Wave of Cancer Breakthroughs

FIRST LOOK

The Next Wave of Cancer Breakthroughs

Monday Morning | 8AM – 12PM

Please join us as some of our most creative investigators describe their most promising commercially related research. Rapid-fire presentations by two dozen early-career Harvard Medical School faculty will highlight compelling new discoveries and insights that will be the cancer care products of the future. If identifying new high impact cancer technology is your passion—as an investor, company leader, donor, entrepreneur or investigator—this session is for you. These young stars from Brigham and Women's Hospital, Massachusetts General Hospital and Dana-Farber Cancer Institute will each describe their work in highly organized 10-minute sessions.

Speakers

All speakers are affiliated with Harvard Medical School

Cyril Benes, PhD, MGH
Priscilla Brastianos, MD, MGH
Mark Cobbold, MD, PhD, MGH
Ryan Corcoran, MD, PhD, MGH
Shawn Demehri, MD, PhD, MGH
Daniela Dinulescu, PhD, BWH
Wilhelm Haas, PhD, MGH
Lida Hariri, MD, PhD, MGH
Aditi Hazra, PhD, BWH
Jayender Jagadeesan, PhD, BWH
Hakho Lee, PhD, MGH
Alexander Lin, PhD, BWH
Sandra McAllister, PhD, BWH
Mikael Pittet, PhD, MGH
Miguel Rivera, MD, MGH
Sandro Santagata, MD, PhD, BWH
Shiladitya Sengupta, PhD, BWH
Paul Shyn, MD, BWH
Matthew Steinhauser, MD, BWH
Shannon Stott, PhD, MGH
Mario Suva, MD, PhD, MGH
David Ting, MD, MGH

Discovery

C A F É

a World Medical Innovation Forum Event

DISCOVERY CAFÉ LUNCH

Enjoy Lunch with Top Cancer Leadership
from across Partners HealthCare

Monday Lunch | 12PM – 1:30PM

Top faculty from Brigham and Women's Hospital, Massachusetts General Hospital and Dana-Farber Cancer Institute will host intimate lunch discussions on developments in their field and their own research. Forum attendees are invited to engage with these internationally renowned leaders on topics ranging from the integration of specific oncology therapies to the newest diagnostic methods. This will be an exciting and energized session with abundant opportunities for direct exchanges with these world leaders. Open registration for tables by topic/speaker (8 guests per table) is available as part of World Forum registration.

Speakers

All speakers are affiliated with Harvard Medical School

Kenneth Anderson, MD, BWH	Jeannie Lee, MD, PhD, MGH
Monica Bertagnolli, MD, BWH	Maximo Loda, MD, BWH
Joan Brugge, PhD, HMS	Jay Loeffler, MD, MGH
George Demetri, MD, Dana-Farber	Robert Martuza, MD, MGH
Don Dizon, MD, MGH	Marcela Maus, MD, PhD, MGH
David Fisher, MD, PhD, MGH	Ann Partridge, MD, Dana-Farber
Keith Flaherty, MD, MGH	Scott Rodig, MD, PhD, BWH
Levi Garraway, MD, PhD, Dana-Farber	Deborah Schrag, MD, BWH, Dana-Farber
Jeffrey Golden MD, BWH	Arlene Sharpe, MD, PhD, BWH, Dana-Farber
Daniel Haber, MD, PhD, MGH	Julie Silver, MD, Spaulding
Elizabeth Henske, MD, BWH, Dana-Farber	Kimberly Stegmaier, MD, Dana-Farber
Theodore Hong, MD, MGH	Guillermo Tearney, MD, PhD, MGH
John Iafrate, MD, MGH	Ralph Weissleder, MD, PhD, MGH
Katherine Janeway, MD, Dana-Farber	Jonathan Whetstone, PhD, MGH
Keith Joung, MD, PhD, MGH	
Cigall Kadoch, PhD, Dana-Farber	

Featured Speakers

Kenneth Anderson, MD

Director, Jerome Lipper Multiple Myeloma Center, Kraft Family Professor of Medicine, Harvard Medical School

Usman Azam, MD

Global Head, Cell & Gene Therapies Unit, Novartis

Julia Beaver, MD

Acting Clinical Team Leader, Division of Oncology Products 1, CDER, FDA

Monica Bertagnolli, MD

Chief, Division of Surgical Oncology, Brigham and Women's Hospital, Professor of Surgery, Harvard Medical School

James Bradner, MD

President, Novartis Institutes for BioMedical Research

Robert Bradway

CEO, Amgen

Troy Brennan, MD

EVP and CMO, CVS Health

Joan Brugge, PhD

Professor, Director, Ludwig Center, Harvard Medical School

Giovanni Caforio, MD

CEO, Bristol-Myers Squibb

Bruce Chabner, MD

Cancer Center Clinical Director Emeritus, Massachusetts General Hospital, Professor, Department of Medicine, Harvard Medical School

Andy Chan, MD

Program Director, Gastroenterology Training Program, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School

Antonio Chiocca, MD, PhD

Chairman, Neurosurgery, Brigham and Women's Hospital Professor of Surgery, Harvard Medical School

Robert Copeland, PhD

President of Research and Chief Scientific Officer, Epizyme

Newt Crenshaw

Vice President of North America Oncology, Eli Lilly

Francis Cuss, MD

Executive Vice President and Chief Scientific Officer, R&D, Bristol-Myers Squibb

Thomas Daniel, MD

Chairman, Celgene Research

Marc de Garidel

CEO, Ipsen

Louis DeGennaro, PhD

CEO, The Leukemia & Lymphoma Society

George Demetri, MD

Director, Center for Sarcoma and Bone Oncology, Senior Vice President for Experimental Therapeutics, Institute Physician, Dana-Farber Cancer Institute

Sheila Dharmarajan

Head of Business Development, Zelnick Media Capital

Keith Dionne, PhD

CEO, Constellation Pharmaceuticals

Don Dizon, MD

Clinical Co-Director, Gynecologic Oncology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School

Glenn Dranoff, MD

Global Head of Exploratory Immunology, Novartis Institutes for Biomedical Research

Jens Eckstein, PhD

President, SR One

Helmy Eltoukhy, PhD

CEO, Guardant Health

Jeffrey Engelman, MD, PhD

Director, Thoracic Oncology and Director, Molecular Therapeutics, Medical Oncology, Massachusetts General Hospital, Laurel Schwartz Associate Professor of Medicine, Harvard Medical School

Maurice Ferre, MD

CEO, Insightec

Tim Ferris, MD

Senior Vice President of Population Health Management, Partners HealthCare

David Fisher, MD, PhD

Chief, Dermatology, Massachusetts General Hospital, Edward Wigglesworth Professor of Dermatology, Harvard Medical School

Keith Flaherty, MD

Director, Clinical Research, Cancer Center, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School

Pat Fortune, PhD

Senior Market Sector Leader, Partners Innovation

Jean-François Formela, MD

Partner, Atlas Ventures

Jamie Freedman, MD, PhD

Senior Vice President, Global Clinical Development MedImmune

Mark Frohlich, MD

EVP, Portfolio Strategy, Juno Therapeutics

Levi Garraway, MD, PhD

Director, Center for Cancer Precision Medicine, Assistant Professor of Medicine, Medical Oncology Service, Dana-Farber Cancer Institute, Associate Professor of Medicine, Harvard Medical School

Kathy Giusti

Founder and Executive Chairman, MMRF

Jeffrey Golden, MD

Chair of Pathology, Brigham and Women's Hospital, Ramzi S. Cotran Professor of Pathology, Harvard Medical School

Richard Gonzalez

CEO, AbbVie

Marc Grodman, MD

CEO, BioReference Laboratories

Daphne Haas-Kogan, MD

Chair, Department of Radiation Oncology, Dana-Farber Cancer Institute, Professor of Radiation Oncology, Harvard Medical School

Daniel Haber, MD, PhD

Director, Massachusetts General Hospital Cancer Center, Kurt J. Isselbacher/Peter D. Schwartz Professor of Oncology, Harvard Medical School

Nir Hacohen, PhD

Immunologist, MGH Center for Immunology and Inflammatory Diseases, MGH Research Scholar, Associate Professor, Medicine, Harvard Medical School

William Hait, MD, PhD

Global Head, Janssen R&D, J&J

Sean Harper, MD

Executive Vice President, Research and Development, Amgen

Theodore Hong, MD

Director, Gastrointestinal Radiation Oncology, Massachusetts General Hospital, Associate Professor of Radiation Oncology, Harvard Medical School

Paul Hudson

President, AstraZeneca US, Executive Vice President, AstraZeneca North America

John Iafrate, MD, PhD

Associate in Pathology, Medical Director, Center for Integrated Diagnostics, Massachusetts General Hospital, Professor of Pathology, Harvard Medical School

Joseph Jachinowski

CEO, Mevion Medical Systems

Katherine Janeway, MD

Associate Physician, Dana-Farber Cancer Institute, Assistant Professor, Harvard Medical School

Joseph Jimenez

CEO, Novartis

Keith Joung, MD, PhD

The Jim and Ann Orr MGH Research Scholar, Associate Chief of Pathology for Research, Pathologist, Massachusetts General Hospital, Professor of Pathology, Harvard Medical School

Cigall Kadoch, PhD

Principal Investigator, Pediatric Oncology,
Dana-Farber Cancer Institute,
Assistant Professor, Pediatrics,
Harvard Medical School

Rajiv Kaul

Portfolio Manager and Research Analyst,
Fidelity Investments

Anne Klibanski, MD

Chief Academic Officer,
Partners HealthCare, Laurie Carrol
Guthart Professor of Medicine,
Harvard Medical School

Maria Koehler, MD, PhD

Vice President, Strategy,
Innovation and Collaborations,
Pfizer Oncology Business Unit

Krishna Kumar

CEO, Emerging Business, Phillips

Peter Lebowitz, MD, PhD

Global Therapeutic Area Head,
Oncology, Janssen R&D

David Lee

CEO, Lumicell

Jeannie Lee, MD, PhD

Professor of Genetics,
Massachusetts General Hospital

Jonathan Leff

Partner, Deerfield Management

Gillian Leng, MD

Deputy Chief Executive and Director
of Health and Social Care, NICE

Nick Leschly

CEO, Bluebird Bio

Neal Lindeman, MD

Associate Pathologist, Pathology,
Brigham and Women's Hospital,
Associate Professor, Pathology,
Harvard Medical School

Massimo Loda, MD

Senior Pathologist, Principal Investigator,
Brigham and Women's Hospital,
Dana-Farber Cancer Institute, Professor,
Department of Pathology,
Harvard Medical School

Jay Loeffler, MD

Chair, Radiation Oncology, Massachusetts
General Hospital, Herman and Joan Suit
Professor of Radiation Oncology,
Harvard Medical School

David Louis, MD

Pathologist-in-Chief, Massachusetts
General Hospital, Benjamin Castleman
Professor of Pathology,
Harvard Medical School

Thomas Lynch, MD

CEO, Mass General
Physician's Organization

Mallika Marshall, MD

Health Reporter, WBZ-TV/CBS Boston

Marcela Maus, MD, PhD

Director of Cellular Immunotherapy,
Massachusetts General Hospital, Assistant
Professor, Harvard Medical School

Briggs Morrison, MD

CEO, Syndax Pharmaceuticals

Robert Mulroy

CEO, Merrimack Pharmaceuticals

Betsy Nabel, MD

President, Brigham and Women's
Hospital, Professor of Medicine,
Harvard Medical School

Amir Nashat, PhD

Managing Partner, Polaris Partners

Ann Partridge, MD

Director, Adult Survivorship Program,
Program for Young Women with Breast
Cancer, Dana-Farber Cancer Institute,
Associate Professor of Medicine,
Harvard Medical School

Michael Pellini, MD

CEO, Foundation Medicine

Amy Pollack, MD

Vice President, Medical Affairs, CMO,
Surgical Businesses and Developed
Markets, Covidien

Gary Reedy

CEO, American Cancer Society

David Reese, MD

Senior Vice President,
Translational Sciences, Amgen

Alessandro Riva, MD

Global Head, Oncology Development and
Medical Affairs, Novartis Oncology

James Robinson

President, Astellas Pharma US

Scott Rodig, MD, PhD

Associate Professor,
Brigham and Women's Hospital

Phil Rowlands, PhD

Interim Head, Oncology,
Therapeutic Area Unit, Takeda

Judy Salerno, MD

CEO, Susan G. Komen for the Cure

David Schenkein, MD

CEO, Agios Pharmaceuticals

Deborah Schrag, MD

Chief, Division of Population Sciences,
Medical Oncology, Dana-Farber Cancer
Institute Professor, Medicine,
Harvard Medical School

William Sellers, MD

Vice President and Global Head of
Oncology, Novartis Institutes for
BioMedical Research

Arlene Sharpe, MD, PhD

Leader, Cancer Immunology Brigham and
Women's Hospital, Dana-Farber Cancer
Institute, George Fabyan Professor of
Comparative Pathology,
Harvard Medical School

Sue Siegel

CEO, GE Ventures and Healthymagination

Julie Silver, MD

Staff Physiatrix, Spaulding Rehabilitation
Hospital, Associate Professor, Associate
Chair for Strategic Initiatives, Department
of Physical Medicine and Rehabilitation,
Harvard Medical School

Nancy Simonian, MD

CEO, Syros Pharmaceuticals

Peter Slavin, MD

President, Massachusetts General
Hospital, Professor of Healthcare Policy,
Harvard Medical School

Andy Slavitt

Acting Administrator, CMS

Nancy Snyderman, MD

Medical Advisor,
GE Healthymagination

Risa Stack, PhD

General Manager, New Business Creation,
GE Ventures

Billy Starr

Founder & Executive Director,
Pan-Mass Challenge

Kimberly Stegmaier, MD

Associate Professor, Dana-Farber Cancer
Institute, Harvard Medical School

Bruno Strigini

President, Novartis Oncology

Guillermo Tearney, MD, PhD

Pathology, Mike and Sue Hazard Family
MGH Research Scholar, Massachusetts
General Hospital, Professor of Pathology,
Harvard Medical School

Robert Tepper, MD

Partner, Third Rock Ventures, Adjunct
Professor, Harvard Medical School

Henri Termeer**Claire Thom, PharmD**

Senior Vice President, Global Oncology
Development, Astellas

Meg Tirrell

Biotech and Pharma Reporter, CNBC

David Torchiana, MD

CEO, Partners HealthCare

Mike Vasconcelles, MD

CMO, Unum Therapeutics

Christopher Viehbacher

Managing Partner,
Gurnet Point Capital

Ralph Weissleder, MD, PhD

Director, Center for Systems Biology,
Massachusetts General Hospital,
Professor, Radiology and Systems
Biology, Harvard Medical School

Johnathan Whetstone, PhD

Tepper Family MGH Research Scholar,
Associate Professor of Medicine,
Harvard Medical School

Chuck Wilson, PhD

CEO, Unum Therapeutics

Dow Wilson

CEO, Varian Medical Systems

Note: Speakers subject to change.



Join Us for the 2016 World Medical Innovation Forum

Experience the state-of-the-art in cancer technology, care, and research

Understand the prospects for innovation in a transformed health care industry

See firsthand the breakthrough cancer technologies from across the industry

Forge relationships and exchange information with world-recognized clinicians, investors, entrepreneurs, scientists, CEOs, executives, government leaders, philanthropists, and journalists

BROUGHT TO YOU BY:



215 First Street, Suite 500 | Cambridge, MA 02142

worldmedicalinnovation.org

